Aquestive Therapeutics Growth, Revenue, Number of Employees and Funding
Estimated Revenue & Financials
- Aquestive Therapeutics's estimated revenue is currently $6.7M per year.
- Aquestive Therapeutics received $73.9M in venture funding in August 2018.
- Aquestive Therapeutics's estimated revenue per employee is $49197
- Aquestive Therapeutics's total funding is $76.6M.
- Aquestive Therapeutics has 137 Employees.
- Aquestive Therapeutics grew their employee count by 22% last year.
- Aquestive Therapeutics currently has 1 job openings.
|Theresa Wood||SVP HR|
|Mike Hermanek||Quality Assurance Director|
|Stephen Wargacki||Director of CMC|
|Simon Scholte||Director of Technical Operations|
|Peter Boyd||SVP, Business Process & IT|
|Gary Slatko||SVP & Chief Medical Officer|
|Ed Korenkiewicz||VP, Pricing & Market Access|
|Glen Mott||Regional Sales Director|
|Kara Leslie Whitmore||Regional Sales Director|
|Joseph Crusco||Director Business Development|
What Is Aquestive Therapeutics?
Aquestive Therapeutics is a specialty pharmaceutical company that advances and commercializes medicines to solve critical healthcare problems and meaningfully improve people's lives. Our team asks questions and identifies issues others have not, and builds solutions that empower patients and their caregivers with better ways to manage complex diseases. Our initial focus, supported by our current approved products and late stage pipeline, is to address immediate CNS challenges.keywords:N/A
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Trio, An FCB He...||$7.8M||40||-2%|
|PRI Healthcare ...||$11.5M||56||-5%|
|TAIHO ONCOLOGY ...||$35.8M||194||9%|
|LEO Pharma Inc....||$42.4M||232||3%|
Aquestive Therapeutics News
Aquestive Therapeutics, Inc.'s (NASDAQ:AQST): Aquestive Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, ...
WARREN, N.J., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company ...
Aquestive Therapeutics Inc (NASDAQ:AQST) was the target of a significant decline in short interest during the month of July. As of July 31st, ...
Aquestive Therapeutics Funding
|2018-08-16||$73.9M||Undisclosed||BMO Capital Markets||Article|
Aquestive Therapeutics Executive Hires
|2018-09-12||Lori Braender||SVP General Counsel||Article|
|2019-01-04||Gary Slatko||SVP, Chief Medical Officer||Article|